Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapt Therapeutics Inc (NQ: RAPT )

17.24 -1.07 (-5.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 235,999
Open 18.31
Bid (Size) 15.76 (1)
Ask (Size) 18.50 (1)
Prev. Close 18.31
Today's Range 17.18 - 18.31
52wk Range 15.59 - 31.45
Shares Outstanding 34,358,152
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
Via Benzinga
Analyst Ratings for RAPT Therapeutics
Via Benzinga

Performance

YTD
-7.36%
-7.36%
1 Month
-9.97%
-9.97%
3 Month
-17.35%
-17.35%
6 Month
-1.20%
-1.20%
1 Year
-25.34%
-25.34%

More News

Read More
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
From RAPT Therapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for RAPT Therapeutics
Via Benzinga
Analyst Ratings for RAPT Therapeutics
Via Benzinga
Analyst Expectations for RAPT Therapeutics's Future
Via Benzinga
Recap: RAPT Therapeutics Q1 Earnings
Via Benzinga
The Latest Analyst Ratings for RAPT Therapeutics
Via Benzinga
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Via Benzinga
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports First Quarter 2023 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
From RAPT Therapeutics, Inc.
Via GlobeNewswire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
S&P 500 Rises 1%; Crude Oil Down Over 4%
Via Benzinga
Dow Extends Rebound, Surges 456 Points
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.